Free Trial
→ Nvidia Times 1,000,000 (From Paradigm Press) (Ad)tc pixel
NASDAQ:NCNA

NuCana 8/20/2025 Earnings Report

NuCana logo
$2.92 +0.03 (+1.04%)
Closing price 09/9/2025 04:00 PM Eastern
Extended Trading
$2.97 +0.05 (+1.71%)
As of 09:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

NuCana EPS Results

Actual EPS
-$0.16
Consensus EPS
-$2.75
Beat/Miss
Beat by +$2.59
One Year Ago EPS
N/A

NuCana Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NuCana Announcement Details

Quarter
Date
8/20/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

NuCana's next earnings date is estimated for Monday, November 24, 2025, based on past reporting schedules.

Conference Call Resources

NuCana Earnings Headlines

NuCana plc: NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025
September 5, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-09/66342548-nucana-plc-nucana-to-present-data-on-nuc-7738-s-synergy-with-pd-1-inhibitors-at-the-esmo-congress-2025-399.htm
NuCana Compliant with All Nasdaq Continued Listing Criteria
September 5, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/05/3145243/0/en/nucana-compliant-with-all-nasdaq-continued-listing-criteria.html
Musk Warns. Trump Acts. Your Retirement May Depend on It
With Donald Trump back in the White House, many believe an economic revival could be underway — but it also brings new risks for retirement savers. Traditional 401(k)s and IRAs may leave investors more exposed than they realize. That’s why a Trump-backed IRS strategy is gaining attention. It allows everyday Americans to reposition their retirement savings into real assets like gold and silver — offering both protection and potential upside. A new 2025 Wealth Protection Guide explains exactly how it works.tc pixel
September 10 at 2:00 AM  |  American Alternative (Ad)
NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025
September 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/03/3143493/0/en/nucana-to-present-data-on-nuc-7738-s-synergy-with-pd-1-inhibitors-at-the-esmo-congress-2025.html
NuCana Reports Q2 2025 Financial Results Highlighting Operating Loss
August 20, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/nucana-reports-q2-2025-financial-results-highlighting-operating-loss/ar-AA1KUivq
NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update
August 20, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/20/3136712/0/en/nucana-reports-second-quarter-2025-financial-results-and-provides-business-update.html
See More NuCana Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email.

About NuCana

NuCana (NASDAQ:NCNA) plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure. NUC-3373 is being evaluated in multiple Phase 2 studies, including trials in colorectal and gastric cancers. In addition to NUC-3373, the company is advancing NUC-7738, an innate immune response modulator, through early-stage clinical development. These programs exemplify NuCana’s strategy of applying its ProTide chemistry to diversify treatment options for oncology patients.

Founded in 2013, NuCana has grown from a UK-based research startup into a globally oriented organization with clinical operations and collaborations across North America and Europe. Under the leadership of Chief Executive Officer Alastair Smith, the company continues to expand its clinical footprint, engaging with academic institutions and industry partners to accelerate the development and potential commercialization of its drug candidates. NuCana remains committed to translating its proprietary chemistry platform into differentiated therapies that address unmet medical needs in cancer care.

View NuCana Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles